MedTrace Logo

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

NCT01909492 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-06-22

Study results available
· View outcomes & findings →

Summary

This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

PROCEDURE

Blood Draw

Patients will provide a serum sample for research.

PROCEDURE

Lumbar Puncture

Patients will have a lumbar puncture to obtain CSF.

Sponsors & Collaborators

  • Microstein, LLC

    collaborator UNKNOWN

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Stanley Cohan, MD, PhD · Providence Brain & Spine Institute, Providence Health & Services

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-20
Primary Completion
2023-10-05
Completion
2023-10-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01909492 on ClinicalTrials.gov